sp move, page-10

Hi livas1

Taking a section from the Annual Report under the heading Business Strategy .........progress a range of products through clinical and regulatory milestones before commercialising them in global markets through commercial partners.

I take this to read as being either a straight trade sale or licence with a royalty or fee per sale. I am sure that in previous releases from EMS talk has always been about a trade sale and I can't see any reason to change that strategy. With all due respect to SC and the good work that he is doing, there is no way that I can see that in the foreseeable future that EMS have the skills to turn themselves into a manufacturing/sales/distributer. I think that would be fraught with danger and undo so much that has been gained in the past couple of years.

Roll on the Conference.

kippax